Risk of Venous Thromboembolism in Hospitalized Psoriasis Patients
DOI:
https://doi.org/10.12970/2310-998X.2019.07.04Keywords:
Psoriasis, Epidemiology, Inflammation, Embolism, Thrombosis, Venous Thromboembolism.Abstract
Background: Psoriasis is associated with increased mortality but the underlying pathophysiology has yet to be copiously recognized. There are several models that demonstrate that psoriasis is not only a disease of the skin, but also has major systemic involvement of the internal organs. Psoriasis is a chronic inflammatory skin disease with a wide range of clinical manifestations. The purpose of this article is to evaluate a nationwide database to compare the incidence, prevalence, and inpatient burden of venous thromboembolism in patients with and without psoriasis.
Methods and Results: A cross-sectional study to examine the risk of incidence of VTE among patients with PsO. A total of 31,268 patients (0.4%) were diagnosed with PsO in a sample size of 7,103,377 (99.6%). A greater proportion of patients with PsO experienced either a DVT or PE compared to those who did not have PsO (1.4% vs. 1.2%). 445 patients (1.4%) were diagnosed with a DVT or PE with a p-value of < 0.001 compared to those who did not have psoriasis 85,135 (1.2%). An association with patients who died while in the hospital was found with 1.9% of patients with PsO died when compared with those without PsO.
Conclusion: Psoriasis patients were also noted to have an increased length of hospitalization than the control group. Other factors such as race and socioeconomic factors were also found to have an association with the development with VTEs.
References
Neimann AL, Porter SB, Gelfand JM. Epidemiology of psoriasis. Expert Rev Dermatol 2006; 1: 63-75. https://doi.org/10.1586/17469872.1.1.63
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5): 826-50. https://doi.org/10.1016/j.jaad.2008.02.039
Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol 2008; 143(2): 180-90. https://doi.org/10.1111/j.1365-2141.2008.07323.x
Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117(1): 93-102. https://doi.org/10.1161/CIRCULATIONAHA.107.709204
Holmqvist ME, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 2012; 308: 1350-1356. https://doi.org/10.1001/2012.jama.11741
Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, Sung FC, Kao CH. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2014; 73: 1774-1780. https://doi.org/10.1136/annrheumdis-2013-203380
Romero-Díaz J, García-Sosa I, Sánchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol 2009; 36: 68-75. https://doi.org/10.3899/jrheum.071244
HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2015-2016. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/databases. jsp.
World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd ed. World Health Organization 2004.
SAS Institute Inc. SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary, NC: SAS Institute Inc. 2013.
Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015; 33: 41-55. https://doi.org/10.1016/j.det.2014.09.004
Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-9. https://doi.org/10.7150/ijms.7.284
Morici N, et al. Psoriasis and the risk of acute coronary syndrome in the elderly. Int J Cardiol 2018; 273: 44-46. https://doi.org/10.1016/j.ijcard.2018.07.134
Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013; 126 832 e13-21. https://doi.org/10.1016/j.amjmed.2013.02.024
Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699. https://doi.org/10.1111/j.1538-7836.2007.02450.x
Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009; 23: 225-229. https://doi.org/10.1016/j.blre.2009.07.002
Anderson Jr. FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107(23 Suppl 1): I9-16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6
Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis 2013; 72: 1182-1187. https://doi.org/10.1136/annrheumdis-2012-201669
Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic disease. Arthritis Res Ther 2014; 16: 435. https://doi.org/10.1186/s13075-014-0435-y
Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum 2016; 46: 291-304. https://doi.org/10.1016/j.semarthrit.2016.05.012
Bauersachs R, Riess H, Hach-Wunderle V, Gerlach H, Carnarius H, Eberle S, Rabe E, Schellong S. Impact of gender on the clinical presentation and diagnosis of deep-vein thrombosis. Thromb Haemost 2010; 103(04): 710-717. https://doi.org/10.1160/TH09-10-0705
